Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 4D Molecular Therapeutics (FDMT) stock

Learn how to easily invest in 4D Molecular Therapeutics stock.

4D Molecular Therapeutics, Inc
NASDAQ: FDMT - USD
BIOTECHNOLOGY
$0
-

4D Molecular Therapeutics, Inc is a biotechnology business based in the US. 4D Molecular Therapeutics shares (FDMT) are listed on the NASDAQ and all prices are listed in US Dollars. 4D Molecular Therapeutics employs 88 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in 4D Molecular Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FDMT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

4D Molecular Therapeutics stock price (NASDAQ: FDMT)

Use our graph to track the performance of FDMT stocks over time.

4D Molecular Therapeutics shares at a glance

Information last updated 2021-07-22.
Latest market close$26.56
52-week range$21.40 - $55.11
50-day moving average $25.05
200-day moving average $35.96
Wall St. target price$52.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy 4D Molecular Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy 4D Molecular Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

4D Molecular Therapeutics price performance over time

Historical closes compared with the close of $26.56 from 2021-05-28

1 week (2021-07-15) N/A
1 month (2021-06-25) 17.47%
3 months (2021-04-26) -27.87%
6 months (2021-01-22) N/A
1 year (2020-07-22) N/A
2 years (2019-07-22) N/A
3 years (2018-07-22) N/A
5 years (2016-07-22) N/A

4D Molecular Therapeutics financials

Revenue TTM $12.1 million
Gross profit TTM $-39,426,000
Return on assets TTM -20.44%
Return on equity TTM -44%
Profit margin 0%
Book value $9.08
Market capitalisation $653.9 million

TTM: trailing 12 months

Shorting 4D Molecular Therapeutics shares

There are currently 947,224 4D Molecular Therapeutics shares held short by investors – that's known as 4D Molecular Therapeutics's "short interest". This figure is 5.8% down from 1.0 million last month.

There are a few different ways that this level of interest in shorting 4D Molecular Therapeutics shares can be evaluated.

4D Molecular Therapeutics's "short interest ratio" (SIR)

4D Molecular Therapeutics's "short interest ratio" (SIR) is the quantity of 4D Molecular Therapeutics shares currently shorted divided by the average quantity of 4D Molecular Therapeutics shares traded daily (recently around 182861.77606178). 4D Molecular Therapeutics's SIR currently stands at 5.18. In other words for every 100,000 4D Molecular Therapeutics shares traded daily on the market, roughly 5180 shares are currently held short.

To gain some more context, you can compare 4D Molecular Therapeutics's short interest ratio against those of similar companies.

However 4D Molecular Therapeutics's short interest can also be evaluated against the total number of 4D Molecular Therapeutics shares, or, against the total number of tradable 4D Molecular Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 4D Molecular Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 4D Molecular Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0581% of the tradable shares (for every 100,000 tradable 4D Molecular Therapeutics shares, roughly 58 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against 4D Molecular Therapeutics.

Find out more about how you can short 4D Molecular Therapeutics stock.

4D Molecular Therapeutics share dividends

We're not expecting 4D Molecular Therapeutics to pay a dividend over the next 12 months.

4D Molecular Therapeutics overview

4D Molecular Therapeutics, Inc. , a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca.

Stocks similar to 4D Molecular Therapeutics

Frequently asked questions

What percentage of 4D Molecular Therapeutics is owned by insiders or institutions?
Currently 23.295% of 4D Molecular Therapeutics shares are held by insiders and 65.594% by institutions.
How many people work for 4D Molecular Therapeutics?
Latest data suggests 88 work at 4D Molecular Therapeutics.
When does the fiscal year end for 4D Molecular Therapeutics?
4D Molecular Therapeutics's fiscal year ends in December.
Where is 4D Molecular Therapeutics based?
4D Molecular Therapeutics's address is: 5858 Horton Street, EmeryVille, CA, United States, 94608

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site